New and emerging therapies for advanced or metastatic soft tissue sarcoma.

about

New and emerging therapies for advanced or metastatic soft tissue sarcoma.

Item

http://www.wikidata.org/entity/Q38136098

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

New and emerging therapies for advanced or metastatic soft tissue sarcoma.

@en

type

Item

label

New and emerging therapies for advanced or metastatic soft tissue sarcoma.

@en

prefLabel

New and emerging therapies for advanced or metastatic soft tissue sarcoma.

@en

P1476

New and emerging therapies for advanced or metastatic soft tissue sarcoma.

@en

P2093

Jaime E Anderson

http://www.w3.org/2001/XMLSchema#string

Jennifer E Davis

http://www.w3.org/2001/XMLSchema#string

Suzanne C Gettys

http://www.w3.org/2001/XMLSchema#string

P2860

Dose response evaluation of adriamycin in human neoplasia

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.

A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.

P304

288-297

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1078155213502370

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24022407

http://www.w3.org/2001/XMLSchema#string